Bruker Cellular Analysis (CELL) 10-Q 11 May 21 2021 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2021	Apr. 30, 2021
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2021
Document Transition Report	false
Entity File Number	001-39388
Entity Registrant Name	Berkeley Lights, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	35-2415390
Entity Address, Address Line One	5858 Horton Street, Suite 320
Entity Address, City or Town	Emeryville
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94608
City Area Code	510
Local Phone Number	858-2855
Title of 12(b) Security	Common stock, $0.00005 par value
Trading Symbol	BLI
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		66,724,383
Entity Central Index Key	0001689657
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q1
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 230,165	$ 233,408
Trade accounts receivable	16,432	12,939
Inventory	10,941	11,047
Prepaid expenses and other current assets	8,240	8,175
Total current assets	265,778	265,569
Restricted cash	270	270
Property and equipment, net	17,152	14,544
Operating lease right-of-use assets	16,223	16,718
Other assets	3,528	2,557
Total assets	302,951	299,658
Current liabilities:
Trade accounts payable	6,934	3,491
Accrued expenses and other current liabilities	8,153	8,401
Current portion of notes payable	16,592	11,594
Deferred revenue	7,929	5,482
Total current liabilities	39,608	28,968
Notes payable, net of current portion	3,320	8,301
Deferred revenue, net of current portion	2,301	1,709
Lease liability, long-term	15,356	15,899
Total liabilities	60,585	54,877
Commitments and contingencies (Note 13)
Stockholders’ equity:
Convertible preferred stock, $0.00005 par value. Authorized 10,000,000 shares at March 31, 2021 and December 31, 2020, respectively; no shares issued and outstanding at March 31, 2021 and December 31, 2020	0	0
Common stock, $0.00005 par value. Authorized 300,000,000 shares at March 31, 2021 and December 31, 2020; issued and outstanding 66,384,736 and 64,486,246 shares at March 31, 2021 and December 31, 2020, respectively	4	3
Additional paid-in capital	449,681	436,662
Accumulated deficit	(207,319)	(191,884)
Total stockholders’ equity	242,366	244,781
Total liabilities and stockholders’ equity	$ 302,951	$ 299,658

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Convertible preferred stock, par value (in dollars per share)	$ 0.00005	$ 0.00005
Convertible preferred stock authorized (in shares)	10,000,000
Convertible preferred stock issued (in shares)	0
Convertible preferred stock outstanding (in shares)	0
Common stock, par value (in dollars per share)	$ 0.00005	$ 0.00005
Common stock authorized (in shares)	300,000,000
Common stock issued (in shares)	66,384,736	64,486,246
Common stock outstanding (in shares)	66,384,736	64,486,246

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Revenue:
Total revenue	$ 18,628	$ 13,778
Cost of sales:
Total cost of sales	6,177	3,799
Gross profit	12,451	9,979
Operating expenses:
Research and development	13,027	10,976
General and administrative	8,967	3,997
Sales and marketing	5,606	3,234
Total operating expenses	27,600	18,207
Loss from operations	(15,149)	(8,228)
Other income (expense):
Interest expense	(354)	(357)
Interest income	66	151
Other income (expense), net	19	25
Loss before income taxes	(15,418)	(8,409)
Provision for income taxes	17	16
Net loss and net comprehensive loss	(15,435)	(8,425)
Net loss and net comprehensive loss	$ (15,435)	$ (8,425)
Net loss attributable to common stockholders per share, basic and diluted (in dollars per share)	$ (0.24)	$ (3.02)
Weighted-average shares used in calculating net loss per share, basic and diluted (in shares)	65,259,398	3,047,967
Product
Revenue:
Total revenue	$ 13,533	$ 10,683
Cost of sales:
Total cost of sales	3,703	2,620
Service
Revenue:
Total revenue	5,095	3,095
Cost of sales:
Total cost of sales	$ 2,474	$ 1,179

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	Convertible Preferred Stock	Common Stock	Additional Paid-in Capital	Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2019		50,462,272	3,073,067
Beginning balance at Dec. 31, 2019	$ 83,783	$ 224,769	$ 0	$ 9,314	$ (150,300)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)			8,580
Exercise of stock options	21			21
Stock-based compensation	1,213			1,213
Net loss	(8,425)				(8,425)
Ending balance (in shares) at Mar. 31, 2020		50,462,272	3,081,647
Ending balance at Mar. 31, 2020	76,680	$ 224,769	$ 0	10,636	(158,725)
Beginning balance (in shares) at Dec. 31, 2020		0	64,486,246
Beginning balance at Dec. 31, 2020	244,781	$ 0	$ 3	436,662	(191,884)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)			1,778,130
Exercise of stock options	6,362		$ 1	6,361
Vesting of restricted stock units (in shares)			5,000
Employee stock purchase plan (in shares)			115,360
Employee stock purchase plan	2,157			2,157
Stock-based compensation	4,501			4,501
Net loss	(15,435)				(15,435)
Vesting of shares subject to repurchase from early exercised options	88			88
Ending balance (in shares) at Mar. 31, 2021		0	66,384,736
Ending balance at Mar. 31, 2021	$ 242,366	$ 0	$ 4	$ 449,681	$ (207,319)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Cash flows from operating activities:
Net loss	$ (15,435)	$ (8,425)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation	1,345	1,319
Stock-based compensation	4,494	1,179
Amortization of operating lease right-of-use assets	495	468
Non-cash interest and other (income) expense related to debt and note receivable agreements	18	17
Provision for excess and obsolete inventory	44	6
Loss on disposal and impairment of property and equipment	13	13
Changes in operating assets and liabilities:
Trade accounts receivable	(3,493)	(687)
Inventory	(2,744)	(3,469)
Prepaid expenses, other current assets and other assets	(1,036)	613
Trade accounts payable	2,690	1,160
Deferred revenue	3,039	(2,026)
Accrued expenses and other current liabilities	(429)	336
Operating lease liabilities	(361)	(492)
Net cash used in operating activities	(11,360)	(9,988)
Cash flows from investing activities:
Purchase of property and equipment	(402)	(760)
Net cash used in investing activities	(402)	(760)
Cash flows from financing activities:
Proceeds from issuance of common stock upon exercise of stock options	6,362	21
Proceeds from issuance of common stock under employee stock purchase plan	2,157	0
Net cash provided by financing activities	8,519	21
Net decrease in cash and cash equivalents and restricted cash	(3,243)	(10,727)
Cash and cash equivalents and restricted cash at beginning of period	233,678	81,303
Cash and cash equivalents and restricted cash at end of period	$ 230,435	$ 70,576

The Company and Basis of Presen

The Company and Basis of Presentation	3 Months Ended
	Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
The Company and Basis of Presentation	The Company and Basis of Presentation Description of Business Berkeley Lights, Inc. (the “Company” or “Berkeley Lights”) is a leading Digital Cell Biology company focused on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products. Berkeley Lights’ platform is a fully integrated, end-to-end solution, comprised of proprietary consumables, including our OptoSelect chips and reagent kits, advanced automation systems and advanced application and workflow software. In 2017, Berkeley Lights incorporated BLI Europe International, Ltd. as a wholly-owned subsidiary in the United Kingdom to support Berkeley Lights’ planned expansion in Europe. In the third quarter of 2020, Berkeley Lights established a wholly owned foreign operating entity in China to further expand its operations. Berkeley Lights and its consolidated subsidiaries are hereinafter referred to as the “Company”. The Company’s headquarters are in Emeryville, California. Basis of Presentation The accompanying unaudited condensed consolidated financial statements of Berkeley Lights in this Quarterly Report have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the instructions to Form 10-Q and Article 10 of Regulation of S-X of the U.S. Securities and Exchange Commission (“the SEC”). Accordingly, these interim financial statements do not include all of the information and footnotes required by U.S. GAAP for annual financial statements. In the opinion of Berkeley Lights’ management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of our financial information have been included. The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the amounts reported in its condensed consolidated financial statements and the accompanying notes. Despite the Company’s intentions to establish accurate estimates and reasonable assumptions, actual results could differ materially from such estimates and assumptions. Operating results for the three months ended March 31, 2021 are not necessarily indicative of the results that may be expected for the year ending December 31, 2021 or for any other period. The condensed consolidated balance sheet at December 31, 2020 has been derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These interim financial statements and notes should be read in conjunction with the audited financial statements and notes thereto for the year ended December 31, 2020 included in the Annual Report on Form 10-K filed with the SEC on March 12, 2021. Liquidity The Company has experienced losses from its operations since its inception and has relied primarily on equity and debt financing to fund its operations to date. For the three months ended March 31, 2021, the Company had a consolidated net loss of $15.4 million and as of March 31, 2021 had an accumulated deficit of $207.3 million and unrestricted cash and cash equivalents of $230.2 million. Management expects to continue to incur significant expenses for the foreseeable future and to incur operating losses in the near term while the Company makes investments to support its anticipated growth. The Company believes that its cash and cash equivalents balance as of March 31, 2021 provides sufficient capital resources to continue its operations for at least 12 months from the issuance date of the accompanying consolidated financial statements. Initial Public Offering The Company’s registration statement on Form S-1 related to its initial public offering (“IPO”) was declared effective on July 16, 2020 by the SEC, and the Company’s common stock began trading on the Nasdaq Global Select Market on July 17, 2020. On July 21, 2020, the Company closed its IPO, in which the Company sold 9,315,000 shares of common stock (which included 1,215,000 shares that were sold pursuant to the full exercise of the IPO underwriters’ option to purchase additional shares) at a price to the public of $22.00 per share. Including the option exercise, the Company received aggregate net proceeds of $187.9 million after deducting offering costs, underwriting discounts and commissions of $17.0 million. Immediately prior to the completion of the IPO, 50,462,272 shares of convertible preferred stock then outstanding converted into an equivalent number of shares of common stock.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Significant accounting policies The Company’s significant accounting policies are disclosed in its Annual Report on Form 10-K for the year ended December 31, 2020 filed with the Securities and Exchange Commission and have not materially changed during the three months ended March 31, 2021. Revenue Recognition The Company derives revenue from two primary sources, primarily product and service revenues. Product revenues are comprised primarily of direct platform sales and product consumables revenues. Service revenues are comprised of revenue from joint development agreements, service and warranty, platform support and feasibility studies on the Company’s platforms. Revenues are recognized net of applicable taxes imposed on the related transaction. The Company recognizes revenue when the Company satisfies the performance obligations under the terms of a contract and control of its products and services is transferred to its customers in an amount that reflects the consideration the Company expects to receive from its customers in exchange for those products and services. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract based on stand-alone selling price, and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. The Company considers a performance obligation satisfied once it has transferred control of a good or service to the customer, meaning the customer has the ability to use and obtain the benefit of the good or service. The Company’s agreements with customers often include multiple performance obligations, which can sometimes be included in separate contracts entered into within a reasonably short period of time. The Company considers an entire customer arrangement to determine if separate contracts should be considered combined for the purposes of revenue recognition. In order to determine the stand-alone selling price, the Company conducts a periodic analysis to determine whether various goods or services have an observable stand-alone selling price as well as to identify significant changes to current stand-alone selling prices. If the Company does not have an observable stand-alone selling price for a particular good or service, then the stand-alone selling price for that particular good or service is estimated using an approach that maximizes the use of observable inputs. The Company’s process for determining stand-alone selling price requires judgment and considers multiple factors that are reasonably available and maximizes the use of observable inputs that may vary over time depending upon the unique facts and circumstances related to each performance obligation. The Company believes that this method results in an estimate that represents the price the Company would charge for the product offerings if they were sold separately. For most of its performance obligations, the Company has established stand-alone selling price as a range rather than a single value, such range being plus or minus 15% of the weighted average of observable prices. If the contractually stated prices of all the performance obligations in a contract fall within their respective stand-alone selling price ranges, the Company will allocate the transaction price at the contractually stated amounts. In situations where the contractually stated price for one or more performance obligations in a contract fall(s) outside of their respective stand-alone selling price range, the Company will use the mid-point of the respective stand-alone selling price range for performance obligations in the contract priced outside of their respective stand-alone selling price range(s) and the contract values for performance obligations priced within their respective stand-alone selling price range(s), to allocate the transaction price on a relative stand-alone selling price basis. Taxes, such as sales, value-add and other taxes, collected from customers concurrent with revenue generating activities and remitted to governmental authorities are not included in revenue. Shipping and handling costs associated with outbound freight are accounted for as a fulfillment cost and are included in cost of sales. The following describes the nature of the Company’s primary types of revenue and the revenue recognition policies and significant payment terms as they pertain to the types of transactions the Company enters into with its customers. Product revenues Product revenues are comprised of two major revenue streams, direct platform sales and consumables. Direct platform sales revenues are comprised of advanced automation systems (including fully-paid workflow licenses) as well as Culture Station instruments. Direct platform sales also include revenue from subscription arrangements in which customers are able to subscribe to a specific workflow and pay a quarterly fee over a fixed period of time which covers the annual workflow license, the advanced automation system, as well as warranty and service. Consumables revenues are comprised of OptoSelect chips required to run the system as well as reagent kits. The Company’s standard arrangement with its customers is generally a purchase order or an executed contract. Revenue on product sales is recognized when control has transferred to the customer which typically occurs when the product has been shipped to the customer, risk of loss has transferred to the customer and the Company has a present right to payment for the system, chip or kit, as applicable. In certain limited circumstances when a product sale includes client acceptance provisions, the Company will first assess such terms to determine if the control of the good is being transferred to the customer in accordance with the agreed-upon specifications in the contract. To the extent that such acceptance provisions can be objectively determined to be aligned with the standard specifications of the arrangement, are defined and easily evaluated for completion, as well as do not afford the customer any additional rights or create additional performance obligations for the Company, such provisions would be determined perfunctory and would not preclude revenue recognition presuming all other criteria are met. If such acceptance provisions are considered to be substantive, revenue is recognized either when client acceptance has been obtained, client acceptance provisions have lapsed, or the Company has objective evidence that the criteria specified in the client acceptance provisions have been satisfied. Payment terms are generally thirty to ninety days from the date of invoicing. On a limited basis, the Company also enters into fixed-term sales-type lease arrangements with certain qualified customers. Revenue from sales-type lease arrangements is generally recognized in a manner consistent with platform systems, assuming all other revenue recognition criteria have been met. Service revenues Service revenues primarily consist of joint development agreements, service and warranty, training and installation services, platform support and feasibility studies on the Company’s advanced automation systems and workflows. The Company’s services are provided primarily on a fixed fee basis; from time to time these fixed fee contracts may be invoiced at the outset of the arrangements. The Company recognizes revenue from the sale of extended warranty and enhanced service warranty arrangements over the respective period, while revenue on feasibility studies is recognized over time, using an input measure of progress based on costs incurred to date relative to total expected costs. Revenue on platform support is recognized as the services are performed. Service contracts are typically short-term in nature. Payment terms are generally thirty to ninety days from the date of invoicing. Joint development agreements are agreements whereby the Company provides services for the development of customized advanced automation systems, workflows or for customized workflows and consumables to meet a specific customer’s needs. Such contracts can be executed on a time-and-materials basis as well as include defined milestones associated with these development activities over extended periods of time, some in excess of twenty-four months. Typically, there are formal customer acceptance clauses as each milestone is completed, and an approval to proceed with the next milestone is generally required. The Company recognizes revenue over time, using an input measure of progress based on costs incurred to date relative to total expected costs. Payment terms are generally thirty to ninety days from the achievement of each milestone. The Company places a constraint on a variable consideration estimate that focuses on possible future downward revenue adjustments (i.e., revenue reversals) if there is uncertainty that could prevent a faithful depiction of the consideration to which the Company expects to be entitled to. The constraint estimate is reassessed at each reporting date until the uncertainty is resolved. Contract assets and contract liabilities Contract assets include amounts where revenue recognized exceeds the amount invoiced to the customer and the right to payment is not solely subject to the passage of time. The Company’s contract asset balances of $3.8 million and $2.7 million as of March 31, 2021 and December 31, 2020, respectively, are primarily from its sales-type lease arrangements as well as its development and feasibility study agreements. The Company does not have impairment losses associated with contracts with customers for the three months ended March 31, 2021 and 2020. Contract liabilities consist of fees invoiced or paid by the Company’s customers for which the associated services have not been performed and revenues have not been recognized based on the Company’s revenue recognition criteria described above. Such amounts are reported as deferred revenue on the condensed consolidated balance sheets. Deferred revenue that is expected to be recognized during the following twelve months is recorded as a current liability and the remaining portion is recorded as non-current. Contract assets and contract liabilities are reported in a net position on an individual contract basis at the end of each reporting period. Contract assets are classified as current or long-term on the condensed consolidated balance sheet based on the timing of when the Company expects to complete the related performance obligations and invoice the customers. Contract liabilities are classified as current or long-term on the condensed consolidated balance sheet based on the timing when the revenue recognition associated with the related customer payments and invoicing is expected to occur. Costs to obtain or fulfill a contract Origination costs relate primarily to the payment of incentive bonuses that are directly related to sales transactions. Fulfillment costs generally include the direct cost of services such as platform support and feasibility studies. Origination and fulfillment costs that are internal to the Company are generally expensed when incurred because most of those costs are incurred concurrently with the delivery of the related goods and services, which are predominantly recognized at a point in time or are short-term in nature. The origination costs that are related to long-term development agreements are capitalized and amortized over the relevant service period. The origination costs that are related to long-term development agreements are not material as of March 31, 2021 and 2020. Stock-Based Compensation The Company maintains an incentive compensation plan under which incentive stock options, nonqualified stock options and restricted stock units (“RSUs”) are granted primarily to employees and non-employee consultants. Stock-based compensation expense for stock-based awards is based on the grant date fair value. The Company determines the fair value of RSUs based on the closing value of its stock price listed on Nasdaq at the date of the grant. The Company estimates the fair value of stock option awards on the grant date using the Black-Scholes option-pricing model. The fair value of stock option awards is recognized as compensation expense on a straight-line basis over the requisite service period in which the awards are expected to vest and forfeitures are recognized as they occur. Stock option awards that include a service condition and a performance condition are considered expected to vest when the performance condition is probable of being met. Compensation expense associated with performance awards that are determined to be probable of achievement is recognized over the requisite service period, provided the grantee remains an employee or consultant of the Company through each applicable vesting date. The Company records a cumulative adjustment to compensation expense for performance-based awards if there is a change in determination of whether it is probable that the performance condition will be achieved. If the performance goals are not achieved, no compensation expense is recognized and any previously recognized compensation expense is reversed. The Company records forfeitures as they occur. Product Warranties The Company provides a 13-month assurance-type warranty on its platforms and chip consumables. Upon shipment, the Company establishes an accrual for estimated warranty expenses based on historical data and trends of product reliability and costs of repairing and replacing defective products. The Company exercises judgment in estimating the expected product warranty costs, using data such as the actual and projected product failure rates, estimated repair costs, freight, material, labor, and overhead costs. While management believes that historical experience provides a reliable basis for estimating such warranty cost, unforeseen quality issues or component failure rates could result in future costs in excess of such estimates, or alternatively, improved quality and reliability in the Company’s products could result in actual expenses that are below those currently estimated. Leases The Company determines the initial classification and measurement of its right-of-use assets and lease liabilities at the lease commencement date and thereafter, if modified. The lease term includes any renewal options and termination options that the Company is reasonably assured to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its incremental borrowing rate. The incremental borrowing rate is determined by using the rate of interest that the Company would pay to borrow on a collateralized basis an amount equal to the lease payments for a similar term and in a similar economic environment. Lease expense for operating leases is recognized on a straight-line basis over the reasonably assured lease term based on the total lease payments and is included in operating expenses in the condensed consolidated statements of operations and comprehensive loss. For all leases, rent payments that are based on a fixed index or rate at the lease commencement date are included in the measurement of lease assets and lease liabilities at the lease commencement date. The Company has elected the practical expedient to not separate lease and non-lease components. The Company’s non-lease components are primarily related to property maintenance and insurance, which varies based on future outcomes, and thus is recognized in rent expense when incurred. The Company also acts as a lessor to provide equipment financing through sales-type lease arrangements with certain qualified customers. Revenue from sales-type leases is presented on a gross basis when the company enters into a lease to realize value from a product that it would otherwise sell in its ordinary course of business. Amounts due and receivable under these arrangements are recorded at the outset of the arrangement as a contract asset in prepaid expenses and other current assets and other assets until such time that invoices are issued in accordance with the terms of the lease, at which point they are recorded as trade accounts receivable in the condensed consolidated balance sheets. Net Loss Attributable to Common Stockholders Per Share Net loss attributable to common stockholders per share is computed by dividing the weighted-average number of common shares outstanding for the period. Diluted net loss per share reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted into common stock; however, potential common equivalent shares are excluded if their effect is anti-dilutive. In computing diluted net loss per share, the Company utilizes the treasury stock method. The Company applies the two-class method to compute basic and diluted net loss or income per share when it has issued shares that meet the definition of participating securities. The two-class method determines net (loss) or income per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires net (loss) income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to share in the earnings as if all net (loss) income for the period had been distributed. The Company’s convertible preferred stock participates in any dividends declared by the Company and are therefore considered to be participating securities. The participating securities are not required to participate in the losses of the Company, and therefore during periods of loss there is no allocation required under the two-class method. Recently Issued and Adopted Accounting Standards In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes , which is intended to simplify various aspects related to the accounting for income taxes. The Company adopted ASU 2019-12 effective January 1, 2021; such adoption did not have a material impact on the Company’s condensed consolidated financial statements and related disclosures.

Significant Risks and Uncertain

Significant Risks and Uncertainties Including Business and Credit Concentrations	3 Months Ended
	Mar. 31, 2021
Risks and Uncertainties [Abstract]
Significant Risks and Uncertainties Including Business and Credit Concentrations	Significant Risks and Uncertainties Including Business and Credit Concentrations Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents and trade receivables. The Company’s cash and cash equivalents are held by large, credit worthy financial institutions. The Company invests its excess cash in money market funds. The Company has established guidelines relative to credit ratings, diversification and maturities that seek to maintain safety and liquidity. Deposits in these banks may exceed the amounts of insurance provided on such deposits. To date, the Company has not experienced any losses on its deposits of cash and cash equivalents. The Company controls credit risk through credit approvals, credit limits, and monitoring procedures. The Company performs periodic credit evaluations of its customers and generally does not require collateral. Accounts receivable are recorded net of an allowance for doubtful accounts. The allowance for doubtful accounts is based on management’s assessment of the collectability of specific customer accounts and the aging of the related invoices and represents the Company’s best estimate of probable credit losses in its existing trade accounts receivable. At each of March 31, 2021 and 2020, the Company had not recorded any material allowance for doubtful accounts. Most of the Company’s customers are located in the United States and Asia Pacific. For the three months ended March 31, 2021, two customers accounted for 11% and 10% of revenue. For the three months ended March 31, 2020, six customers accounted for 17%, 14%, 13%, 13%, 12% and 12% of revenue.

Revenue From Contracts With Cus

Revenue From Contracts With Customers	3 Months Ended
	Mar. 31, 2021
Revenue from Contract with Customer [Abstract]
Revenue From Contracts With Customers	Revenue From Contracts With Customers Disaggregation of revenue The following table depicts the disaggregation of revenue by type of customer or sales channel, market segment as defined by nature of workflows and activities of the end customer and timing of revenue recognition (in thousands): Three months ended March 31, 2021 2020 Type of Sales Channel Direct sales channel $ 10,439 $ 11,981 Distributor channel 8,189 1,797 Net revenues $ 18,628 $ 13,778 Market Antibody therapeutics $ 15,114 $ 11,821 Synthetic biology 1,984 1,606 Gene therapy 1,225 — Cell therapy 305 351 Net revenues $ 18,628 $ 13,778 Timing of Revenue Recognition Goods and services transferred at a point in time $ 13,064 $ 10,688 Goods and services transferred over time 5,564 3,090 Net revenues $ 18,628 $ 13,778 Revenues by market are determined by the revenue associated with workflows that the Company’s customers are utilizing, primarily on our Beacon platform, or by the nature of the workflows that the Company is developing under joint development and partnership agreements. Revenues by geographical markets are presented in Note 15 to these condensed consolidated financial statements. Performance Obligations A significant number of the Company’s product and service sales, as well as its feasibility study arrangements, are short-term in nature with a contract term of one year or less. For those contracts, the Company has utilized the practical expedient in ASC 606-10-50-14 exempting the Company from disclosure of the transaction price allocated to remaining performance obligations if the performance obligation is part of a contract that has an original expected duration of one year or less. As of March 31, 2021, the aggregate amount of remaining performance obligations that are unsatisfied or partially unsatisfied related to customer contracts w as $6.4 million, which includes deferred revenue on the Company’s condensed consolidated balance sheets, of which approximately 37% is e xpected to be recognized to revenue in the next 12 months, with the remainder recognized afterwards. Contract balances The following table provides information about receivables, contract assets and deferred revenue from contracts with customers (in thousands): March 31, December 31, Trade accounts receivable $ 16,432 $ 12,939 Contract assets, which are included in “Prepaid expenses and other current assets” 1,407 1,310 Contract assets, long-term, which are included in “Other assets” 2,403 1,375 Deferred revenue (current) 7,929 5,482 Deferred revenue (non-current) 2,301 1,709 The contract liabilities of $10.2 million and $7.2 million as of March 31, 2021 and December 31, 2020, respectively, consisted of deferred revenue related to extended warranty service agreements and advanced billings on advanced automation systems arrangements. Revenue recorded during the three months ended March 31, 2021 i ncluded $2.5 million of previously deferred revenue that was included in contract liabilities as of December 31, 2020. Sales-type lease arrangements The Company also enters into sales-type lease arrangements with certain qualified customers. Revenue related to lease elements from sales-type leases is presented as product revenue and was $1.7 million and none for the three months ended March 31, 2021 and 2020, respectively. The following tables presents the future maturity of the Company’s fixed-term customer leases and reconciles the undiscounted cash flows from the amounts due from customers under such arrangements as of March 31, 2021 (in thousands): Year ending December 31, Sales-Type Remainder of 2021 $ 1,328 2022 2,098 2023 445 2024 and thereafter 853 Total undiscounted cash flows $ 4,724 Less: unearned income 741 Total amounts due from customers, gross $ 3,983

Balance Sheet Accounts

Balance Sheet Accounts	3 Months Ended
	Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Balance Sheet Accounts	Balance Sheet Accounts Inventory The following table shows the components of inventory (in thousands): March 31, December 31, Raw materials $ 6,184 $ 6,675 Finished goods 4,757 4,372 Total $ 10,941 $ 11,047 Prepaid expenses and other current assets The following table shows the components of prepaid expenses and other current assets (in thousands): March 31, December 31, Contract asset $ 1,407 $ 1,310 Vendor deposits 1,363 1,346 Deferred costs 357 292 Prepaid insurance 1,427 2,401 Other 3,686 2,826 Total $ 8,240 $ 8,175 Accrued expenses and other current liabilities The following table shows the components of accrued expenses and other current liabilities (in thousands): March 31, December 31, Accrued payroll and employee related expenses $ 3,419 $ 4,152 Lease liability – short-term 2,090 1,909 Accrued product warranty 1,268 1,271 Accrued legal expenses 896 606 Other 480 463 Total $ 8,153 $ 8,401

Fair Value of Financial Instrum

Fair Value of Financial Instruments	3 Months Ended
	Mar. 31, 2021
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Fair Value of Financial Instruments Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The categorization of a financial instrument within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement. The carrying amounts of the Company’s cash equivalents, accounts receivable and accounts payable approximate fair value due to their relatively short maturities. The Company classifies its cash equivalents, which are comprised primarily of money market funds, within Level 1, as it uses quoted market prices in the determination of fair value. The following tables set forth the fair value of the Company’s financial assets and liabilities by level within the fair value hierarchy (in thousands): March 31, Quoted Prices Significant Significant Assets Cash equivalents $ 25,134 $ 25,134 $ — $ — Total $ 25,134 $ 25,134 $ — $ — December 31, Quoted Prices Significant Significant Assets Cash equivalents $ 25,133 $ 25,133 $ — $ — Total $ 25,133 $ 25,133 $ — $ — The carrying values and fair values of the Company’s financial instruments not measured at fair value were as follows (in thousands): March 31, 2021 December 31, 2020 Carrying Fair Value Carrying Fair Value Long-term debt, including current maturities $ 19,912 $ 19,592 $ 19,895 $ 19,949 The Company estimated the fair value of its long-term debt using a market-based approach that considers an average cost of debt. The Company has incorporated its own credit risk for all liability fair value measurements. Such fair value measurements are considered Level 2 under the fair value hierarchy. The Company did not have any transfers of financial assets measured at fair value on a recurring basis to or from Level 1, Level 2 or Level 3 for any of the periods presented.

Property and Equipment, net

Property and Equipment, net	3 Months Ended
	Mar. 31, 2021
Property, Plant and Equipment [Abstract]
Property and Equipment, net	Property and Equipment, net Property and equipment, net comprised the following (in thousands): March 31, December 31, Equipment, tooling and molds $ 24,295 $ 21,118 Computer software and equipment 2,301 2,153 Furniture, fixtures and other 1,751 1,739 Leasehold improvements 5,603 5,597 Construction in process 874 275 Total property and equipment $ 34,824 $ 30,882 Less: Accumulated depreciation (17,672) (16,338) Property and equipment, net $ 17,152 $ 14,544 Total depreciation expense for the three months ended March 31, 2021 and 2020 was $1.3 million and $1.3 million, respectively. During the three months ended March 31, 2021 and 2020, losses on the impairment and disposal of property and equipment was not material.

Leases

Leases	3 Months Ended
	Mar. 31, 2021
Leases [Abstract]
Leases	Leases The Company leases office, manufacturing, distribution and laboratory facilities in Emeryville, California under multiple operating leases totaling approximately 77,844 square feet. All of the leases expire on March 31, 2028. In addition, the Company also leases multiple facilities in Shanghai, China under operating leases that expire at various dates, including additional office and laboratory facilities under an operating lease agreement that was entered into in July 2020. These leases expire at various dates, the latest of which is August 2023. Certain of the Emeryville leases contain options to early terminate the lease and options to extend the lease for an additional term. However, the Company is not reasonably certain to exercise any of these options. The monthly base rental rate of the leases is subject to adjustment upon renewal based on then current market rental conditions. Future payments associated with the Company’s operating lease liabilities as of March 31, 2021 is as follows (in thousands): Operating leases Undiscounted lease payments for the year ending December 31, Remainder of 2021 $ 2,490 2022 3,258 2023 3,284 2024 3,338 2025 3,439 Thereafter 8,127 Total undiscounted lease payments 23,936 Less: implied interest (5,073) Less: tenant improvement allowances receivable (1,417) Present value of operating lease payments 17,446 Less: current portion (2,090) Total long-term operating lease liabilities $ 15,356 Rent expense for the three months ended March 31, 2021 and 2020 was $0.8 million and $0.6 million, respectively. Under the terms of the lease agreements, the Company is also responsible for certain variable lease payments that are not included in the measurement of the lease liability. Variable lease payments for operating leases were $0.5 million and $0.3 million for the three months ended March 31, 2021 and 2020, respectively, including non-lease components such as common area maintenance fees. The following information represents supplemental disclosure for the statement of cash flows related to operating leases (in thousands): Three months ended March 31, 2021 Cash paid for amounts included in the measurement of lease liabilities $ 691 The following summarizes additional information related to operating leases: March 31, 2021 Weighted-average remaining lease term (years) 6.93 Weighted-average discount rate 7.03 %

Notes Payable

Notes Payable	3 Months Ended
	Mar. 31, 2021
Debt Disclosure [Abstract]
Notes Payable	Notes Payable In May 2018, the Company entered into a Loan and Security Agreement with East West Bank (the “EWB Loan Agreement”) providing it the ability to borrow up to $20.0 million. The EWB Loan Agreement has a term of 48 months and carries an interest only period through May 2021, such interest only period subject to extension based on certain cash and revenue metrics. In March 2020, the EWB Loan Agreement was amended to extend the interest only period by an additional twelve months through May 2021. There were no other changes to the loan agreement associated with this amendment. The note payable is collateralized by substantially all the assets of the Company, excluding intellectual property, which is subject to a negative pledge. The note carries an interest at a fixed rate of 6.73% per annum. The following is a schedule of payments due on notes payable as of March 31, 2021 (in thousands): March 31, Year Ending December 31: Remainder of 2021 $ 12,495 2022 8,475 Total payments due 20,970 Less: Interest payments, loan discounts and financing costs (1,058) Current portion, less loan discounts and financing costs (16,592) Notes payable, net of current portion $ 3,320

Stock Compensation Plans

Stock Compensation Plans	3 Months Ended
	Mar. 31, 2021
Share-based Payment Arrangement [Abstract]
Stock Compensation Plans	Stock Compensation Plans 2011 Equity Incentive Plan As of March 31, 2021, the number of shares of common stock issuable under the 2011 Equity Incentive Plan, as amended (the “2011 Plan”), was 6,938,283 shares, including shares issuable upon the exercise of outstanding awards. Following the adoption of the 2020 Incentive Award Plan in July 2020, any awards outstanding under the 2011 Plan continue to be governed by their existing terms but no further awards may be granted under the 2011 Plan. 2020 Incentive Award Plan In July 2020, the Company’s Board of Directors approved the 2020 Incentive Award Plan (the “2020 Plan”). The initial number of shares authorized and available for issuance in connection with the grant of future awards is 6,750,000. As of March 31, 2021, the number of shares remaining for issuance under the 2020 Plan was 7,577,297, which includes awards granted and outstanding under the 2011 Plan that have been forfeited or lapsed unexercised after the effective date of the 2020 Plan. 2020 Employee Stock Purchase Plan In July 2020, the Company’s Board of Directors approved the 2020 Employee Stock Purchase Plan (the “ESPP”). A total of 612,150 shares of common stock was initially reserved for issuance under the ESPP. The price at which common stock is purchased under the ESPP is equal to 85% of the fair market value of the common stock on the first day of the offering period or purchase date, whichever is lower. During the three months ended March 31, 2021, 115,360 shares of common stock were issued under the ESPP. As of March 31, 2021, there were 1,142,002 shares available for issuance in connection with the current and future offering periods under the ESPP. Stock-based compensation Stock-based compensation related to the Company's stock-based awards was recorded as an expense and allocated as follows (in thousands): Three months ended March 31, 2021 2020 Cost of sales $ 42 $ 6 Research and development 1,061 511 General and administrative 1,372 529 Sales and marketing 2,019 133 Total stock-based compensation $ 4,494 $ 1,179

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2021
Income Tax Disclosure [Abstract]
Income Taxes	Income TaxesThe Company’s provision for income taxes was $17,000 and $16,000, respectively, for the three months ended March 31, 2021 and 2020. The Company maintains a full valuation allowance on its deferred tax assets, and intends to do so until there is sufficient evidence to support the reversal of all or some portion of these allowances.

Statements of Cash Flows

Statements of Cash Flows	3 Months Ended
	Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Statements of Cash Flows	Statements of Cash Flows The supplemental cash flow information consists of the following (in thousands): Three months ended March 31, 2021 2020 Cash paid for interest $ 337 $ 340 Non-cash investing and financing activities Accrued issuance costs $ — $ 207 Inventory transferred to property and equipment $ 2,813 $ — Change in accounts payable and accrued liabilities related to purchases of property and equipment $ 751 $ (34) Release of repurchase rights on early exercised options $ — $ 88

Commitment and Contingencies

Commitment and Contingencies	3 Months Ended
	Mar. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Legal Proceedings From time to time, the Company may be involved in legal and administrative proceedings and claims of various types. The Company records a liability in its financial statements for these matters when a loss is known and considered probable and the amount can be reasonably estimated. The Company does not recognize gain contingencies until they are realized. Legal costs incurred relating to loss contingencies are expensed as incurred. In July 2020, AbCellera Biologics Inc. (“AbCellera”) filed a complaint in the United States District Court for the District of Delaware, alleging that the Company infringed and continues to infringe, directly and indirectly, the following patents exclusively licensed by AbCellera by making, using, offering for sale, selling and/or importing the Company’s Beacon and Culture Station instruments and the OptoSelect chips, and sale of the Opto Plasma B Discovery Workflow: U.S. Patent Nos. 10,107,812, 10,274,494, 10,466,241, 10,578,618, 10,697,962, 10,087,408, 10,421,936 and 10,704,018 (“AbCellera I”). In August 2020, AbCellera filed a second complaint in the United States District Court for the District of Delaware, making the same allegations with regard to U.S. Patent Nos. 10,718,768, 10,738,270, 10,746,737, and 10,753,933 (“AbCellera II”). In September 2020, AbCellera filed amended complaints in each of AbCellera I and AbCellera II adding The University of British Columbia as a named plaintiff. Also in September 2020, AbCellera and The University of British Columbia filed a third complaint in the United States District Court for the District of Delaware, making the same allegations with regard to U.S. Patent Nos. 10,775,376, 10,775,377, and 10,775,378 (“AbCellera III”). AbCellera and The University of British Columbia are seeking, among other things, judgment of infringement, a permanent injunction and damages (including lost profits, a reasonable royalty, reasonable costs and attorney’s fees and treble damages for willful infringement). In addition to procedural motions, the Company has filed an answer and counterclaims in response to each of the AbCellera I, AbCellera II and AbCellera III lawsuits. The Company’s counterclaims in each lawsuit include counts for declaratory judgment of non-infringement of the asserted patents, for declaratory judgment of invalidity of the asserted patents and for declaratory judgment of unenforceability of the asserted patents due to inequitable conduct. The Company filed a motion to transfer the AbCellera I, AbCellera II and AbCellera III lawsuits to the United States District Court for the Northern District of California, which was granted and where the lawsuits have been consolidated and are now pending. On May 6, 2021, and pursuant to Court Order, AbCellera and The University of British Columbia reduced, without prejudice, the asserted patents in the case to the following: US Patent Nos. 10,087,408, 10,421,936, 10,738,270, 10,697,962, 10,753,933, 10,775,376 and 10,775,378. In August 2020, the Company filed a complaint in the United States District Court for the Northern District of California against AbCellera and Lineage BioSciences, Inc., an entity previously acquired by AbCellera. The complaint includes two counts of unfair competition and one count of a declaratory judgment of non-infringement of U.S. Patent No. 10,058,839. The Company is seeking, among other things, damages and a judgment of non-infringement. In October 2020, the Company filed an amended complaint asserting the same three counts and AbCellera and Lineage filed a motion to dismiss the amended complaint, which was granted, without prejudice, in part. The unfair competition claims remain pending. The Company believes that the patent assertions by AbCellera and The University of British Columbia are without merit and intends to defend itself vigorously. The Company also intends to proceed with its claims and counterclaims against AbCellera and The University of British Columbia. Outcomes in litigation can be uncertain and it is possible a court may disagree with the Company’s positions. An adverse determination in these lawsuits could subject the Company to significant liabilities, require it to seek licenses from or pay royalties to AbCellera and/or The University of British Columbia, or prevent it from manufacturing, selling or using certain of its products, any of which could have a material adverse effect on the Company’s business, financial condition, results of operations and prospects. No provision has been made for litigation because the Company believes that it is not probable that a liability had been incurred as of March 31, 2021. The Company is not currently involved in any other claims or legal actions, nor is management aware of any potential claims or legal actions, for which the ultimate disposition could have a material adverse effect on the Company’s financial position, results of operations, or liquidity. Product Warranty The table below represents the activity in the product warranty accrual included in accrued expenses and other current liabilities on the condensed consolidated balance sheets (in thousands): Three months ended March 31, 2021 2020 Balance, beginning of period $ 1,271 $ 1,065 Adjustments to existing warranties (218) (122) Provision for new warranties 375 330 Settlement of pre-existing warranties (160) (80) Balance, end of period $ 1,268 $ 1,193

Net Loss Attributable to Common

Net Loss Attributable to Common Stockholders Per Share	3 Months Ended
	Mar. 31, 2021
Earnings Per Share [Abstract]
Net Loss Attributable to Common Stockholders Per Share	Net Loss Attributable to Common Stockholders Per Share Potentially issuable shares of common stock include shares issuable upon the exercise of outstanding employee stock option awards. Awards granted with performance conditions are excluded from the shares used to compute diluted earnings per share until the performance conditions associated with the awards are met. The following table sets forth the computation of basic and diluted earnings per common share (in thousands, except share and per share data): Three months ended March 31, 2021 2020 Numerator Net loss attributable to common stockholders $ (15,435) $ (8,425) Cumulative undeclared dividends on Series D convertible preferred stock — (797) Net loss attributable to common stockholders, basic and diluted $ (15,435) $ (9,222) Denominator Weighted-average shares used to compute net income per share, basic and diluted 65,259,398 3,047,967 Net loss per share Net loss per share attributable to common stockholders, basic and diluted $ (0.24) $ (3.02) Since the Company was in a loss position for all periods presented, basic net loss per share attributable to common stockholders is the same as diluted net loss per share attributable to common stockholders, as the inclusion of all potential shares of common stock outstanding would have been anti-dilutive. The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods presented as they had an anti-dilutive effect: Three months ended March 31, 2021 2020 Convertible preferred stock (on an if-converted basis) — 50,462,272 Options to purchase common stock 8,399,147 10,456,747 Restricted stock units 356,725 — Restricted shares of common stock related to early exercise of options — 27,032 Warrants to purchase Series C convertible preferred stock — 136,519 Total 8,755,872 61,082,570

Segments

Segments	3 Months Ended
	Mar. 31, 2021
Segment Reporting [Abstract]
Segments	Segments Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision maker is its Chief Executive Officer. The Company has one business activity and there are no segment managers who are held accountable for operations. Accordingly, the Company has a single reportable segment structure. The Company’s principal operations and decision-making functions are located in the United States. The following table provides the Company’s revenues by geographical market based on the location where the services were provided or to which product was shipped (in thousands): Three months ended March 31, 2021 2020 North America $ 7,362 $ 8,481 Asia Pacific 8,431 4,860 Europe 2,835 437 $ 18,628 $ 13,778 North America includes the United States and related territories. Asia Pacific also includes Australia. As of March 31, 2021 and December 31, 2020, substantially all of the Company’s long-lived assets were located in the United States of America.

The Company and Basis of Pres_2

The Company and Basis of Presentation (Policies)	3 Months Ended
	Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements of Berkeley Lights in this Quarterly Report have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the instructions to Form 10-Q and Article 10 of Regulation of S-X of the U.S. Securities and Exchange Commission (“the SEC”). Accordingly, these interim financial statements do not include all of the information and footnotes required by U.S. GAAP for annual financial statements. In the opinion of Berkeley Lights’ management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of our financial information have been included. The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the amounts reported in its condensed consolidated financial statements and the accompanying notes. Despite the Company’s intentions to establish accurate estimates and reasonable assumptions, actual results could differ materially from such estimates and assumptions. Operating results for the three months ended March 31, 2021 are not necessarily indicative of the results that may be expected for the year ending December 31, 2021 or for any other period. The condensed consolidated balance sheet at December 31, 2020 has been derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These interim financial statements and notes should be read in conjunction with the audited financial statements and notes thereto for the year ended December 31, 2020 included in the Annual Report on Form 10-K filed with the SEC on March 12, 2021.
Revenue Recognition	Revenue Recognition The Company derives revenue from two primary sources, primarily product and service revenues. Product revenues are comprised primarily of direct platform sales and product consumables revenues. Service revenues are comprised of revenue from joint development agreements, service and warranty, platform support and feasibility studies on the Company’s platforms. Revenues are recognized net of applicable taxes imposed on the related transaction. The Company recognizes revenue when the Company satisfies the performance obligations under the terms of a contract and control of its products and services is transferred to its customers in an amount that reflects the consideration the Company expects to receive from its customers in exchange for those products and services. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract based on stand-alone selling price, and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. The Company considers a performance obligation satisfied once it has transferred control of a good or service to the customer, meaning the customer has the ability to use and obtain the benefit of the good or service. The Company’s agreements with customers often include multiple performance obligations, which can sometimes be included in separate contracts entered into within a reasonably short period of time. The Company considers an entire customer arrangement to determine if separate contracts should be considered combined for the purposes of revenue recognition. In order to determine the stand-alone selling price, the Company conducts a periodic analysis to determine whether various goods or services have an observable stand-alone selling price as well as to identify significant changes to current stand-alone selling prices. If the Company does not have an observable stand-alone selling price for a particular good or service, then the stand-alone selling price for that particular good or service is estimated using an approach that maximizes the use of observable inputs. The Company’s process for determining stand-alone selling price requires judgment and considers multiple factors that are reasonably available and maximizes the use of observable inputs that may vary over time depending upon the unique facts and circumstances related to each performance obligation. The Company believes that this method results in an estimate that represents the price the Company would charge for the product offerings if they were sold separately. For most of its performance obligations, the Company has established stand-alone selling price as a range rather than a single value, such range being plus or minus 15% of the weighted average of observable prices. If the contractually stated prices of all the performance obligations in a contract fall within their respective stand-alone selling price ranges, the Company will allocate the transaction price at the contractually stated amounts. In situations where the contractually stated price for one or more performance obligations in a contract fall(s) outside of their respective stand-alone selling price range, the Company will use the mid-point of the respective stand-alone selling price range for performance obligations in the contract priced outside of their respective stand-alone selling price range(s) and the contract values for performance obligations priced within their respective stand-alone selling price range(s), to allocate the transaction price on a relative stand-alone selling price basis. Taxes, such as sales, value-add and other taxes, collected from customers concurrent with revenue generating activities and remitted to governmental authorities are not included in revenue. Shipping and handling costs associated with outbound freight are accounted for as a fulfillment cost and are included in cost of sales. The following describes the nature of the Company’s primary types of revenue and the revenue recognition policies and significant payment terms as they pertain to the types of transactions the Company enters into with its customers. Product revenues Product revenues are comprised of two major revenue streams, direct platform sales and consumables. Direct platform sales revenues are comprised of advanced automation systems (including fully-paid workflow licenses) as well as Culture Station instruments. Direct platform sales also include revenue from subscription arrangements in which customers are able to subscribe to a specific workflow and pay a quarterly fee over a fixed period of time which covers the annual workflow license, the advanced automation system, as well as warranty and service. Consumables revenues are comprised of OptoSelect chips required to run the system as well as reagent kits. The Company’s standard arrangement with its customers is generally a purchase order or an executed contract. Revenue on product sales is recognized when control has transferred to the customer which typically occurs when the product has been shipped to the customer, risk of loss has transferred to the customer and the Company has a present right to payment for the system, chip or kit, as applicable. In certain limited circumstances when a product sale includes client acceptance provisions, the Company will first assess such terms to determine if the control of the good is being transferred to the customer in accordance with the agreed-upon specifications in the contract. To the extent that such acceptance provisions can be objectively determined to be aligned with the standard specifications of the arrangement, are defined and easily evaluated for completion, as well as do not afford the customer any additional rights or create additional performance obligations for the Company, such provisions would be determined perfunctory and would not preclude revenue recognition presuming all other criteria are met. If such acceptance provisions are considered to be substantive, revenue is recognized either when client acceptance has been obtained, client acceptance provisions have lapsed, or the Company has objective evidence that the criteria specified in the client acceptance provisions have been satisfied. Payment terms are generally thirty to ninety days from the date of invoicing. On a limited basis, the Company also enters into fixed-term sales-type lease arrangements with certain qualified customers. Revenue from sales-type lease arrangements is generally recognized in a manner consistent with platform systems, assuming all other revenue recognition criteria have been met. Service revenues Service revenues primarily consist of joint development agreements, service and warranty, training and installation services, platform support and feasibility studies on the Company’s advanced automation systems and workflows. The Company’s services are provided primarily on a fixed fee basis; from time to time these fixed fee contracts may be invoiced at the outset of the arrangements. The Company recognizes revenue from the sale of extended warranty and enhanced service warranty arrangements over the respective period, while revenue on feasibility studies is recognized over time, using an input measure of progress based on costs incurred to date relative to total expected costs. Revenue on platform support is recognized as the services are performed. Service contracts are typically short-term in nature. Payment terms are generally thirty to ninety days from the date of invoicing. Joint development agreements are agreements whereby the Company provides services for the development of customized advanced automation systems, workflows or for customized workflows and consumables to meet a specific customer’s needs. Such contracts can be executed on a time-and-materials basis as well as include defined milestones associated with these development activities over extended periods of time, some in excess of twenty-four months. Typically, there are formal customer acceptance clauses as each milestone is completed, and an approval to proceed with the next milestone is generally required. The Company recognizes revenue over time, using an input measure of progress based on costs incurred to date relative to total expected costs. Payment terms are generally thirty to ninety days from the achievement of each milestone. The Company places a constraint on a variable consideration estimate that focuses on possible future downward revenue adjustments (i.e., revenue reversals) if there is uncertainty that could prevent a faithful depiction of the consideration to which the Company expects to be entitled to. The constraint estimate is reassessed at each reporting date until the uncertainty is resolved. Contract assets and contract liabilities Contract assets include amounts where revenue recognized exceeds the amount invoiced to the customer and the right to payment is not solely subject to the passage of time. The Company’s contract asset balances of $3.8 million and $2.7 million as of March 31, 2021 and December 31, 2020, respectively, are primarily from its sales-type lease arrangements as well as its development and feasibility study agreements. The Company does not have impairment losses associated with contracts with customers for the three months ended March 31, 2021 and 2020. Contract liabilities consist of fees invoiced or paid by the Company’s customers for which the associated services have not been performed and revenues have not been recognized based on the Company’s revenue recognition criteria described above. Such amounts are reported as deferred revenue on the condensed consolidated balance sheets. Deferred revenue that is expected to be recognized during the following twelve months is recorded as a current liability and the remaining portion is recorded as non-current. Contract assets and contract liabilities are reported in a net position on an individual contract basis at the end of each reporting period. Contract assets are classified as current or long-term on the condensed consolidated balance sheet based on the timing of when the Company expects to complete the related performance obligations and invoice the customers. Contract liabilities are classified as current or long-term on the condensed consolidated balance sheet based on the timing when the revenue recognition associated with the related customer payments and invoicing is expected to occur. Costs to obtain or fulfill a contract Origination costs relate primarily to the payment of incentive bonuses that are directly related to sales transactions. Fulfillment costs generally include the direct cost of services such as platform support and feasibility studies.
Stock-Based Compensation	Stock-Based Compensation The Company maintains an incentive compensation plan under which incentive stock options, nonqualified stock options and restricted stock units (“RSUs”) are granted primarily to employees and non-employee consultants. Stock-based compensation expense for stock-based awards is based on the grant date fair value. The Company determines the fair value of RSUs based on the closing value of its stock price listed on Nasdaq at the date of the grant. The Company estimates the fair value of stock option awards on the grant date using the Black-Scholes option-pricing model. The fair value of stock option awards is recognized as compensation expense on a straight-line basis over the requisite service period in which the awards are expected to vest and forfeitures are recognized as they occur. Stock option awards that include a service condition and a performance condition are considered expected to vest when the performance condition is probable of being met. Compensation expense associated with performance awards that are determined to be probable of achievement is recognized over the requisite service period, provided the grantee remains an employee or consultant of the Company through each applicable vesting date. The Company records a cumulative adjustment to compensation expense for performance-based awards if there is a change in determination of whether it is probable that the performance condition will be achieved. If the performance goals are not achieved, no compensation expense is recognized and any previously recognized compensation expense is reversed. The Company records forfeitures as they occur.
Product Warranties	Product Warranties The Company provides a 13-month assurance-type warranty on its platforms and chip consumables. Upon shipment, the Company establishes an accrual for estimated warranty expenses based on historical data and trends of product reliability and costs of repairing and replacing defective products. The Company exercises judgment in estimating the expected product warranty costs, using data such as the actual and projected product failure rates, estimated repair costs, freight, material, labor, and overhead costs. While management believes that historical experience provides a reliable basis for estimating such warranty cost, unforeseen quality issues or component failure rates could result in future costs in excess of such estimates, or alternatively, improved quality and reliability in the Company’s products could result in actual expenses that are below those currently estimated.
Leases	Leases The Company determines the initial classification and measurement of its right-of-use assets and lease liabilities at the lease commencement date and thereafter, if modified. The lease term includes any renewal options and termination options that the Company is reasonably assured to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its incremental borrowing rate. The incremental borrowing rate is determined by using the rate of interest that the Company would pay to borrow on a collateralized basis an amount equal to the lease payments for a similar term and in a similar economic environment. Lease expense for operating leases is recognized on a straight-line basis over the reasonably assured lease term based on the total lease payments and is included in operating expenses in the condensed consolidated statements of operations and comprehensive loss. For all leases, rent payments that are based on a fixed index or rate at the lease commencement date are included in the measurement of lease assets and lease liabilities at the lease commencement date. The Company has elected the practical expedient to not separate lease and non-lease components. The Company’s non-lease components are primarily related to property maintenance and insurance, which varies based on future outcomes, and thus is recognized in rent expense when incurred. The Company also acts as a lessor to provide equipment financing through sales-type lease arrangements with certain qualified customers. Revenue from sales-type leases is presented on a gross basis when the company enters into a lease to realize value from a product that it would otherwise sell in its ordinary course of business. Amounts due and receivable under these arrangements are recorded at the outset of the arrangement as a contract asset in prepaid expenses and other current assets and other assets until such time that invoices are issued in accordance with the terms of the lease, at which point they are recorded as trade accounts receivable in the condensed consolidated balance sheets.
Leases	Leases The Company determines the initial classification and measurement of its right-of-use assets and lease liabilities at the lease commencement date and thereafter, if modified. The lease term includes any renewal options and termination options that the Company is reasonably assured to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its incremental borrowing rate. The incremental borrowing rate is determined by using the rate of interest that the Company would pay to borrow on a collateralized basis an amount equal to the lease payments for a similar term and in a similar economic environment. Lease expense for operating leases is recognized on a straight-line basis over the reasonably assured lease term based on the total lease payments and is included in operating expenses in the condensed consolidated statements of operations and comprehensive loss. For all leases, rent payments that are based on a fixed index or rate at the lease commencement date are included in the measurement of lease assets and lease liabilities at the lease commencement date. The Company has elected the practical expedient to not separate lease and non-lease components. The Company’s non-lease components are primarily related to property maintenance and insurance, which varies based on future outcomes, and thus is recognized in rent expense when incurred. The Company also acts as a lessor to provide equipment financing through sales-type lease arrangements with certain qualified customers. Revenue from sales-type leases is presented on a gross basis when the company enters into a lease to realize value from a product that it would otherwise sell in its ordinary course of business. Amounts due and receivable under these arrangements are recorded at the outset of the arrangement as a contract asset in prepaid expenses and other current assets and other assets until such time that invoices are issued in accordance with the terms of the lease, at which point they are recorded as trade accounts receivable in the condensed consolidated balance sheets.
Net Loss Attributable to Common Stockholders Per Share	Net Loss Attributable to Common Stockholders Per Share Net loss attributable to common stockholders per share is computed by dividing the weighted-average number of common shares outstanding for the period. Diluted net loss per share reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted into common stock; however, potential common equivalent shares are excluded if their effect is anti-dilutive. In computing diluted net loss per share, the Company utilizes the treasury stock method. The Company applies the two-class method to compute basic and diluted net loss or income per share when it has issued shares that meet the definition of participating securities. The two-class method determines net (loss) or income per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires net (loss) income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to share in the earnings as if all net (loss) income for the period had been distributed. The Company’s convertible preferred stock participates in any dividends declared by the Company and are therefore considered to be participating securities. The participating securities are not required to participate in the losses of the Company, and therefore during periods of loss there is no allocation required under the two-class method.
Recently Issued and Adopted Accounting Standards	Recently Issued and Adopted Accounting Standards In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes , which is intended to simplify various aspects related to the accounting for income taxes. The Company adopted ASU 2019-12 effective January 1, 2021; such adoption did not have a material impact on the Company’s condensed consolidated financial statements and related disclosures.

Revenue From Contracts With C_2

Revenue From Contracts With Customers (Tables)	3 Months Ended
	Mar. 31, 2021
Revenue from Contract with Customer [Abstract]
Schedule of disaggregation of revenue	The following table depicts the disaggregation of revenue by type of customer or sales channel, market segment as defined by nature of workflows and activities of the end customer and timing of revenue recognition (in thousands): Three months ended March 31, 2021 2020 Type of Sales Channel Direct sales channel $ 10,439 $ 11,981 Distributor channel 8,189 1,797 Net revenues $ 18,628 $ 13,778 Market Antibody therapeutics $ 15,114 $ 11,821 Synthetic biology 1,984 1,606 Gene therapy 1,225 — Cell therapy 305 351 Net revenues $ 18,628 $ 13,778 Timing of Revenue Recognition Goods and services transferred at a point in time $ 13,064 $ 10,688 Goods and services transferred over time 5,564 3,090 Net revenues $ 18,628 $ 13,778
Schedule of receivables, contract assets and deferred revenue from contracts with customers	The following table provides information about receivables, contract assets and deferred revenue from contracts with customers (in thousands): March 31, December 31, Trade accounts receivable $ 16,432 $ 12,939 Contract assets, which are included in “Prepaid expenses and other current assets” 1,407 1,310 Contract assets, long-term, which are included in “Other assets” 2,403 1,375 Deferred revenue (current) 7,929 5,482 Deferred revenue (non-current) 2,301 1,709
Schedule of sales-type lease maturity	The following tables presents the future maturity of the Company’s fixed-term customer leases and reconciles the undiscounted cash flows from the amounts due from customers under such arrangements as of March 31, 2021 (in thousands): Year ending December 31, Sales-Type Remainder of 2021 $ 1,328 2022 2,098 2023 445 2024 and thereafter 853 Total undiscounted cash flows $ 4,724 Less: unearned income 741 Total amounts due from customers, gross $ 3,983

Balance Sheet Accounts (Tables)

Balance Sheet Accounts (Tables)	3 Months Ended
	Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of inventory	The following table shows the components of inventory (in thousands): March 31, December 31, Raw materials $ 6,184 $ 6,675 Finished goods 4,757 4,372 Total $ 10,941 $ 11,047
Schedule of prepaid expenses and other current assets	The following table shows the components of prepaid expenses and other current assets (in thousands): March 31, December 31, Contract asset $ 1,407 $ 1,310 Vendor deposits 1,363 1,346 Deferred costs 357 292 Prepaid insurance 1,427 2,401 Other 3,686 2,826 Total $ 8,240 $ 8,175
Schedule of accrued expenses and other current liabilities	The following table shows the components of accrued expenses and other current liabilities (in thousands): March 31, December 31, Accrued payroll and employee related expenses $ 3,419 $ 4,152 Lease liability – short-term 2,090 1,909 Accrued product warranty 1,268 1,271 Accrued legal expenses 896 606 Other 480 463 Total $ 8,153 $ 8,401

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2021
Fair Value Disclosures [Abstract]
Schedule of financial assets measured at fair value	The following tables set forth the fair value of the Company’s financial assets and liabilities by level within the fair value hierarchy (in thousands): March 31, Quoted Prices Significant Significant Assets Cash equivalents $ 25,134 $ 25,134 $ — $ — Total $ 25,134 $ 25,134 $ — $ — December 31, Quoted Prices Significant Significant Assets Cash equivalents $ 25,133 $ 25,133 $ — $ — Total $ 25,133 $ 25,133 $ — $ —
Schedule of financial instruments not measured at fair value	The carrying values and fair values of the Company’s financial instruments not measured at fair value were as follows (in thousands): March 31, 2021 December 31, 2020 Carrying Fair Value Carrying Fair Value Long-term debt, including current maturities $ 19,912 $ 19,592 $ 19,895 $ 19,949

Property and Equipment, net (Ta

Property and Equipment, net (Tables)	3 Months Ended
	Mar. 31, 2021
Property, Plant and Equipment [Abstract]
Schedule of property and equipment	Property and equipment, net comprised the following (in thousands): March 31, December 31, Equipment, tooling and molds $ 24,295 $ 21,118 Computer software and equipment 2,301 2,153 Furniture, fixtures and other 1,751 1,739 Leasehold improvements 5,603 5,597 Construction in process 874 275 Total property and equipment $ 34,824 $ 30,882 Less: Accumulated depreciation (17,672) (16,338) Property and equipment, net $ 17,152 $ 14,544

Leases (Table)

Leases (Table)	3 Months Ended
	Mar. 31, 2021
Leases [Abstract]
Schedule of operating lease liabilities maturity	Future payments associated with the Company’s operating lease liabilities as of March 31, 2021 is as follows (in thousands): Operating leases Undiscounted lease payments for the year ending December 31, Remainder of 2021 $ 2,490 2022 3,258 2023 3,284 2024 3,338 2025 3,439 Thereafter 8,127 Total undiscounted lease payments 23,936 Less: implied interest (5,073) Less: tenant improvement allowances receivable (1,417) Present value of operating lease payments 17,446 Less: current portion (2,090) Total long-term operating lease liabilities $ 15,356
Schedule of supplemental cash flow information related to operating leases	The following information represents supplemental disclosure for the statement of cash flows related to operating leases (in thousands): Three months ended March 31, 2021 Cash paid for amounts included in the measurement of lease liabilities $ 691
Schedule of additional information related to operating leases	The following summarizes additional information related to operating leases: March 31, 2021 Weighted-average remaining lease term (years) 6.93 Weighted-average discount rate 7.03 %

Notes Payable (Tables)

Notes Payable (Tables)	3 Months Ended
	Mar. 31, 2021
Debt Disclosure [Abstract]
Schedule of payments due on notes payable	The following is a schedule of payments due on notes payable as of March 31, 2021 (in thousands): March 31, Year Ending December 31: Remainder of 2021 $ 12,495 2022 8,475 Total payments due 20,970 Less: Interest payments, loan discounts and financing costs (1,058) Current portion, less loan discounts and financing costs (16,592) Notes payable, net of current portion $ 3,320

Stock Compensation Plans (Table

Stock Compensation Plans (Tables)	3 Months Ended
	Mar. 31, 2021
Share-based Payment Arrangement [Abstract]
Schedule of stock-based compensation	Stock-based compensation related to the Company's stock-based awards was recorded as an expense and allocated as follows (in thousands): Three months ended March 31, 2021 2020 Cost of sales $ 42 $ 6 Research and development 1,061 511 General and administrative 1,372 529 Sales and marketing 2,019 133 Total stock-based compensation $ 4,494 $ 1,179

Statements of Cash Flows (Table

Statements of Cash Flows (Tables)	3 Months Ended
	Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of cash flow, supplemental disclosures	The supplemental cash flow information consists of the following (in thousands): Three months ended March 31, 2021 2020 Cash paid for interest $ 337 $ 340 Non-cash investing and financing activities Accrued issuance costs $ — $ 207 Inventory transferred to property and equipment $ 2,813 $ — Change in accounts payable and accrued liabilities related to purchases of property and equipment $ 751 $ (34) Release of repurchase rights on early exercised options $ — $ 88

Commitment and Contingencies (T

Commitment and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Schedule of product warranty liability	The table below represents the activity in the product warranty accrual included in accrued expenses and other current liabilities on the condensed consolidated balance sheets (in thousands): Three months ended March 31, 2021 2020 Balance, beginning of period $ 1,271 $ 1,065 Adjustments to existing warranties (218) (122) Provision for new warranties 375 330 Settlement of pre-existing warranties (160) (80) Balance, end of period $ 1,268 $ 1,193

Net Loss Attributable to Comm_2

Net Loss Attributable to Common Stockholders Per Share (Tables)	3 Months Ended
	Mar. 31, 2021
Earnings Per Share [Abstract]
Schedule of basic and diluted earnings per common share	The following table sets forth the computation of basic and diluted earnings per common share (in thousands, except share and per share data): Three months ended March 31, 2021 2020 Numerator Net loss attributable to common stockholders $ (15,435) $ (8,425) Cumulative undeclared dividends on Series D convertible preferred stock — (797) Net loss attributable to common stockholders, basic and diluted $ (15,435) $ (9,222) Denominator Weighted-average shares used to compute net income per share, basic and diluted 65,259,398 3,047,967 Net loss per share Net loss per share attributable to common stockholders, basic and diluted $ (0.24) $ (3.02)
Schedule of antidilutive securities excluded from computation of earnings per share	The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods presented as they had an anti-dilutive effect: Three months ended March 31, 2021 2020 Convertible preferred stock (on an if-converted basis) — 50,462,272 Options to purchase common stock 8,399,147 10,456,747 Restricted stock units 356,725 — Restricted shares of common stock related to early exercise of options — 27,032 Warrants to purchase Series C convertible preferred stock — 136,519 Total 8,755,872 61,082,570

Segments (Tables)

Segments (Tables)	3 Months Ended
	Mar. 31, 2021
Segment Reporting [Abstract]
Summary of revenue by geographic areas	The following table provides the Company’s revenues by geographical market based on the location where the services were provided or to which product was shipped (in thousands): Three months ended March 31, 2021 2020 North America $ 7,362 $ 8,481 Asia Pacific 8,431 4,860 Europe 2,835 437 $ 18,628 $ 13,778

The Company and Basis of Pres_3

The Company and Basis of Presentation (Details) - USD ($) $ / shares in Units, $ in Thousands	Jul. 21, 2020	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statement [Line Items]
Net loss attributable to common stockholders		$ (15,435)	$ (8,425)
Accumulated deficit		(207,319)		$ (191,884)
Cash and cash equivalents		$ 230,165		$ 233,408
Convertible Preferred Stock
Organization, Consolidation and Presentation of Financial Statement [Line Items]
Number of convertible preferred stock converted (in shares)	50,462,272
IPO
Organization, Consolidation and Presentation of Financial Statement [Line Items]
Number of shares sold (in shares)	9,315,000
Shares offering price (in dollars per share)	$ 22
Net proceeds after deducting offering costs, underwriting discounts and commissions	$ 187,900
Offering costs, underwriting discounts and commissions	$ 17,000
Underwriters' Option
Organization, Consolidation and Presentation of Financial Statement [Line Items]
Number of shares sold (in shares)	1,215,000

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Revenue Recognition) (Details) $ in Millions	3 Months Ended
	Mar. 31, 2021USD ($)revenueSource	Dec. 31, 2020USD ($)
Disaggregation of Revenue [Line Items]
Revenue sources	2
Percentage of median observable prices	15.00%
Contract asset | $	$ 3.8	$ 2.7
Product
Disaggregation of Revenue [Line Items]
Revenue streams	2
Payment terms	Payment terms are generally thirty to ninety days from the date of invoicing.
Service
Disaggregation of Revenue [Line Items]
Payment terms	Payment terms are generally thirty to ninety days from the date of invoicing.
Joint Development Agreements
Disaggregation of Revenue [Line Items]
Payment terms	Payment terms are generally thirty to ninety days from the achievement of each milestone.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Product Warranty) (Details)	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Product warranty, term	13 months

Significant Risks and Uncerta_2

Significant Risks and Uncertainties Including Business and Credit Concentrations (Details) - Customer	3 Months Ended		12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Revenue | Customer One
Concentration Risk [Line Items]
Concentration risk percentage	11.00%	17.00%
Revenue | Customer Two
Concentration Risk [Line Items]
Concentration risk percentage	10.00%	14.00%
Revenue | Customer Three
Concentration Risk [Line Items]
Concentration risk percentage		13.00%
Revenue | Customer Four
Concentration Risk [Line Items]
Concentration risk percentage		13.00%
Revenue | Customer Five
Concentration Risk [Line Items]
Concentration risk percentage		12.00%
Revenue | Customer Six
Concentration Risk [Line Items]
Concentration risk percentage		12.00%
Accounts Receivable | Customer One
Concentration Risk [Line Items]
Concentration risk percentage	25.00%		42.00%
Accounts Receivable | Customer Two
Concentration Risk [Line Items]
Concentration risk percentage	22.00%		21.00%
Accounts Receivable | Customer Three
Concentration Risk [Line Items]
Concentration risk percentage	12.00%		15.00%
Accounts Receivable | Customer Four
Concentration Risk [Line Items]
Concentration risk percentage	11.00%
Accounts Receivable | Customer Five
Concentration Risk [Line Items]
Concentration risk percentage	11.00%

Revenue From Contracts With C_3

Revenue From Contracts With Customers (Schedule of Disaggregation of Revenue) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Disaggregation of Revenue [Line Items]
Net revenues	$ 18,628	$ 13,778
Goods and services transferred at a point in time
Disaggregation of Revenue [Line Items]
Net revenues	13,064	10,688
Goods and services transferred over time
Disaggregation of Revenue [Line Items]
Net revenues	5,564	3,090
Antibody therapeutics
Disaggregation of Revenue [Line Items]
Net revenues	15,114	11,821
Synthetic biology
Disaggregation of Revenue [Line Items]
Net revenues	1,984	1,606
Gene therapy
Disaggregation of Revenue [Line Items]
Net revenues	1,225	0
Cell therapy
Disaggregation of Revenue [Line Items]
Net revenues	305	351
Direct sales channel
Disaggregation of Revenue [Line Items]
Net revenues	10,439	11,981
Distributor channel
Disaggregation of Revenue [Line Items]
Net revenues	$ 8,189	$ 1,797

Revenue from Contracts with C_4

Revenue from Contracts with Customer (Narrative) (Details) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Revenue from Contract with Customer [Abstract]
Remaining performance obligation	$ 6,400,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Contract liabilities	10,200,000		$ 7,200,000
Contract liability , revenue recognized	2,500,000
Lease income	$ 1,700,000	$ 0
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-04-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation, percentage	37.00%
Remaining performance obligation, period	12 months

Revenue From Contracts With C_5

Revenue From Contracts With Customers (Schedule of Receivables, Contract Assets and Deferred Revenue) (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Revenue from Contract with Customer [Abstract]
Trade accounts receivable	$ 16,432	$ 12,939
Contract assets, which are included in “Prepaid expenses and other current assets”	1,407	1,310
Contract assets, long-term, which are included in “Other assets”	2,403	1,375
Deferred revenue (current)	7,929	5,482
Deferred revenue (non-current)	$ 2,301	$ 1,709

Revenue From Contracts With C_6

Revenue From Contracts With Customers - Sale-type Lease Arrangement (Details) $ in Thousands	Mar. 31, 2021USD ($)
Revenue from Contract with Customer [Abstract]
Remainder of 2021	$ 1,328
2022	2,098
2023	445
2024 and thereafter	853
Total undiscounted cash flows	4,724
Less: unearned income	741
Total amounts due from customers, gross	$ 3,983

Balance Sheet Accounts (Invento

Balance Sheet Accounts (Inventory) (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Raw materials	$ 6,184	$ 6,675
Finished goods	4,757	4,372
Total	$ 10,941	$ 11,047

Balance Sheet Accounts (Prepaid

Balance Sheet Accounts (Prepaid Expenses and Other Current Assets) (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Contract asset	$ 1,407	$ 1,310
Vendor deposits	1,363	1,346
Deferred costs	357	292
Prepaid insurance	1,427	2,401
Other	3,686	2,826
Total	$ 8,240	$ 8,175

Balance Sheet Accounts (Accrued

Balance Sheet Accounts (Accrued Expenses and Other Current Liabilities) (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accrued payroll and employee related expenses	$ 3,419	$ 4,152
Lease liability – short-term	2,090	1,909
Accrued product warranty	1,268	1,271
Accrued legal expenses	896	606
Other	480	463
Total	$ 8,153	$ 8,401

Fair Value of Financial Instr_3

Fair Value of Financial Instruments (Assets and Liabilities) (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash equivalents	$ 25,134	$ 25,133
Total	25,134	25,133
Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash equivalents	25,134	25,133
Total	25,134	25,133
Significant Other Observable Inputs (Level 2)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash equivalents	0	0
Total	0	0
Significant Unobservable Inputs (Level 3)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash equivalents	0	0
Total	$ 0	$ 0

Fair Value of Financial Instr_4

Fair Value of Financial Instruments (Schedule of Financial Instruments Not Measured at Fair Value) (Details) - Significant Other Observable Inputs (Level 2) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, including current maturities	$ 19,912	$ 19,895
Fair Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, including current maturities	$ 19,592	$ 19,949

Property and Equipment, net (Sc

Property and Equipment, net (Schedule of Property and Equipment) (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 34,824	$ 30,882
Less: Accumulated depreciation	(17,672)	(16,338)
Property and equipment, net	17,152	14,544
Equipment, tooling and molds
Property, Plant and Equipment [Line Items]
Total property and equipment	24,295	21,118
Computer software and equipment
Property, Plant and Equipment [Line Items]
Total property and equipment	2,301	2,153
Furniture, fixtures and other
Property, Plant and Equipment [Line Items]
Total property and equipment	1,751	1,739
Leasehold improvements
Property, Plant and Equipment [Line Items]
Total property and equipment	5,603	5,597
Construction in process
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 874	$ 275

Property and Equipment, net (Na

Property and Equipment, net (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Property, Plant and Equipment [Abstract]
Depreciation	$ 1,345	$ 1,319

Leases (Narrative) (Details)

Leases (Narrative) (Details) $ in Millions	3 Months Ended
	Mar. 31, 2021USD ($)ft²	Mar. 31, 2020USD ($)
Leases [Abstract]
Area of lease (sq. ft) | ft²	77,844
Rent expense	$ 0.8	$ 0.6
Variable lease payments	$ 0.5	$ 0.3

Leases (Maturity Schedule of Op

Leases (Maturity Schedule of Operating Lease Liabilities) (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Leases [Abstract]
Remainder of 2021	$ 2,490
2022	3,258
2023	3,284
2024	3,338
2025	3,439
Thereafter	8,127
Total undiscounted lease payments	23,936
Less: implied interest	(5,073)
Less: tenant improvement allowances receivable	(1,417)
Present value of operating lease payments	17,446
Less: current portion	(2,090)	$ (1,909)
Total long-term operating lease liabilities	$ 15,356	$ 15,899

Leases (Schedule of Supplementa

Leases (Schedule of Supplemental Cash Flow Information Related to Operating Leases) (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2021USD ($)
Leases [Abstract]
Cash paid for amounts included in the measurement of lease liabilities	$ 691

Leases (Schedule of Additional

Leases (Schedule of Additional Information Related to Operating Leases) (Details)	Mar. 31, 2021
Leases [Abstract]
Weighted-average remaining lease term (in years)	6 years 11 months 4 days
Weighted-average discount rate	7.03%

Notes Payable (Narrative) (Deta

Notes Payable (Narrative) (Details) - USD ($)	1 Months Ended	3 Months Ended
	May 31, 2018	Mar. 31, 2021	Mar. 31, 2020
Debt Instrument [Line Items]
Interest cost		$ 400,000	$ 400,000
Notes Payable | EWB Loan
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 20,000,000
Note payable, term (in years)	48 months
Interest rate	6.73%

Notes Payable (Schedule of Paym

Notes Payable (Schedule of Payment Due on Notes Payable) (Details) - Notes Payable - EWB Loan $ in Thousands	Mar. 31, 2021USD ($)
Debt Instrument [Line Items]
Remainder of 2021	$ 12,495
2022	8,475
Total payments due	20,970
Interest payments, loan discounts and financing costs	(1,058)
Current portion, less loan discounts and financing costs	(16,592)
Notes payable, net of current portion	$ 3,320

Stock Compensation Plans (Narra

Stock Compensation Plans (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Jul. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation	$ 4,494	$ 1,179
2011 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized (in shares)	6,938,283
2020 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized (in shares)			6,750,000
Number of shares remaining for issuance (in shares)	7,577,297
ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized (in shares)			612,150
Number of shares remaining for issuance (in shares)	1,142,002
Purchase price of common stock, percent	85.00%
Shares issued (in shares)	115,360

Stock Compensation Plans (Stock

Stock Compensation Plans (Stock-Based Compensation) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation	$ 4,494	$ 1,179
Cost of sales
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation	42	6
Research and development
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation	1,061	511
General and administrative
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation	1,372	529
Sales and marketing
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation	$ 2,019	$ 133

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Income Tax Disclosure [Abstract]
Provision for income taxes	$ 17	$ 16

Statements of Cash Flows (Detai

Statements of Cash Flows (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash paid for interest	$ 337	$ 340
Non-cash investing and financing activities
Accrued issuance costs	0	207
Inventory transferred to property and equipment	2,813	0
Change in accounts payable and accrued liabilities related to purchases of property and equipment	751	(34)
Release of repurchase rights on early exercised options	$ 0	$ 88

Commitment and Contingencies (N

Commitment and Contingencies (Narrative) (Details)	1 Months Ended
	Oct. 31, 2020claim	Aug. 31, 2020claim	Mar. 31, 2021USD ($)
Loss Contingencies [Line Items]
Number of counts in amended complaint	3
Loss contingency accrual | $			$ 0
AbCellera, Unfair Competition
Loss Contingencies [Line Items]
Counter claims filed		2
AbCellera, Non-Infringement
Loss Contingencies [Line Items]
Counter claims filed		1

Commitment and Contingencies (P

Commitment and Contingencies (Product Warranty) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Movement in Standard Product Warranty Accrual [Roll Forward]
Balance, beginning of period	$ 1,271	$ 1,065
Adjustments to existing warranties	(218)	(122)
Provision for new warranties	375	330
Settlement of pre-existing warranties	(160)	(80)
Balance, end of period	$ 1,268	$ 1,193

Net Loss Attributable to Comm_3

Net Loss Attributable to Common Stockholders Per Share (Schedule of Basic and Diluted Earnings Per Share) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Numerator
Net loss attributable to common stockholders	$ (15,435)	$ (8,425)
Cumulative undeclared dividends on Series D convertible preferred stock	0	(797)
Net loss attributable to common stockholders, basic and diluted	(15,435)	(9,222)
Net loss attributable to common stockholders, basic and diluted	$ (15,435)	$ (9,222)
Denominator
Weighted-average shares used to compute net income per share, basic and diluted (in shares)	65,259,398	3,047,967
Net loss per share
Net loss attributable to common stockholders per share, basic and diluted (in dollars per share)	$ (0.24)	$ (3.02)

Net Loss Attributable to Comm_4

Net Loss Attributable to Common Stockholders Per Share (Schedule of Antidilutive Securities) (Details) - shares	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from the calculation of net loss per share (in shares)	8,755,872,000	61,082,570,000
Convertible preferred stock (on an if-converted basis)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from the calculation of net loss per share (in shares)	0	50,462,272,000
Options to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from the calculation of net loss per share (in shares)	8,399,147,000	10,456,747,000
Restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from the calculation of net loss per share (in shares)	356,725,000	0
Restricted shares of common stock related to early exercise of options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from the calculation of net loss per share (in shares)	0	27,032,000
Warrants to purchase Series C convertible preferred stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from the calculation of net loss per share (in shares)	0	136,519,000

Segments (Details)

Segments (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenue	$ 18,628	$ 13,778
North America
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenue	7,362	8,481
Asia Pacific
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenue	8,431	4,860
Europe
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenue	$ 2,835	$ 437